Hacettepe University

A Comprehensive Clinicopathologic and Molecular Reappraisal of GLI1 -altered Mesenchymal Tumors with Pooled Outcome Analysis Showing Poor Survival in GLI1 - amplified Versus GLI1- rearranged Tumors. (2024) Saoud C, Agaimy A, Dermawan JK, Chen JF, Rosenblum MK, Dickson BC, Dashti N, et al. Journal article Timing and Modality of Kidney Replacement Therapy in Children and Adolescents (2024) Thumfart J, Wagner S, Kirchner M, Azukaitis K, Bayazit AK, Obrycki L, Canpolat N, et al. Journal article Myeloid sarcoma with RBM15::MRTFA (MKL1) mimicking vascular neoplasm (2024) Gündoğdu F, Agaimy A, Aytaç S, Hazar V, Üner A, Kösemehmetoğlu K Journal article Prolactin and oxytocin: potential targets for migraine treatment (2023) Szewczyk AK, Ulutas S, Aktürk T, Al-Hassany L, Börner C, Cernigliaro F, Kodounis M, et al. Journal article, Review article Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH) (2023) Sarafidis PA, Theodorakopoulou M, Ortiz A, Fernandez-Fernandez B, Nistor I, Schmieder R, Arici M, et al. Journal article Young-GRAPPA (Y-GRAPPA) at the 2022 GRAPPA Annual Meeting: One Year in Y-GRAPPA. Where Do We Stand, Where Do We Go? (2023) Ayan G, Coras R, Grynszpan R, Herrera S, Jethwa H, Johnsson HJ, Silva DL, et al. Journal article Risk factors for multimorbidity in adulthood: A systematic review (2023) Tazzeo C, Zucchelli A, Vetrano DL, Demurtas J, Smith L, Schöne D, Sanchez-Rodriguez D, et al. Journal article, Review article Exploring the Relationship between Socioeconomic Status and Identification of Gifted in Turkey through Critical Systems Thinking (2023) Bıçakçı M Journal article EWSR1::POU2AF3(COLCA2) Sarcoma: An Aggressive, Polyphenotypic Sarcoma With a Head and Neck Predilection. (2023) Koshyk O, Dehner CA, van den Hout MF, Bempt IV, Sciot R, Huang HY, Agaimy A, et al. Journal article Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY (2023) Balmaña J, Fasching P, Couch FJ, Delaloge S, Labidi-Galy I, O’Shaughnessy J, Park YH, et al. Journal article